Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline. (Funded by Eli Lilly; EXPEDI...
Publications
2 shownPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability. (Funded by Eli Lilly; EXPEDITION 1 and 2 ClinicalTrials.gov n...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 2,600
- Institution
- Eli Lilly (Singapore)
External Links
Identifiers
- ORCID
- 0000-0002-9534-0483
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.